This large cohort of patients included heterogeneous clinical conditions, with subjects experiencing first BR, PSA relapse after salvage therapy, PSA persistence after radical prostatectomy, and advanced-stage PCa patients after second-line systemic therapies. This evidence concerns the gene KLK3 and posterior cortical atrophy.